Recent studies conducted by pSivida Corporation, the manufacturer of Iluven, a miniaturized, injectable sustained drug delivery system showed that for the first time, Fluocinolone Acetonide (FA) acted as both a vascular endothelial growth factor (VEGF) inhibitor and as a neuroprotective. That means Fluocinolone Acetonide has properties that inhibit the growth of new blood vessels as well as the ability to protect the neurons from degeneration. These properties support expansion of FA use to other eye conditions such as age-related macular degeneration (AMD) both wet and dry.

AMD is a medical condition usually affecting older adults that result in loss of vision in the center due to damage to the retina. It is considered as the major source of blindness in the elderly aged fifty years and above.

Another condition which could greatly benefit from FA treatment is retinitis pigmentosa, a group of genetic eye conditions wherein symptoms include night blindness (nyctalopia) and reduction of the peripheral visual field (tunnel vision).

In the first study, Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial cells (ARPE – 19). VEGF inhibition is one method of treating wet AMD and is currently the most effective FDA-approved method of treatment for this disease.

In the second study, they found that chronic intravitreal infusion of FA preserves both retinal structure and function.

According to Yahoo finance:

BOSTON–(BUSINESS WIRE)–pSivida Corp. (NASDAQ:PSDV - News)(ASX:PVA - News), a leading drug delivery company, today announced that two newly-published peer reviewed scientific papers showed that Fluocinolone acetonide (FA) both inhibited VEGF production and protected retinal cells and function. These findings support expanding the treatment indications for the company’s lead product, Iluvien, a miniaturized, injectable, sustained-release drug delivery system that releases FA directly into the eye. Iluvien is licensed to Alimera Sciences, of Alpharetta, Georgia and is in Phase III clinical trials for the treatment of Diabetic Macular Edema. Initial data from the 950-patient trials are expected to be reported by the end of the year, with an NDA filing scheduled for early 2010.

Bookmark It

Hide Sites

Tags: age-related macular degeneration, Fluocinolone Acetonide, retinitis pigmentosa, vascular endothelial growth factor

Posted in Steroid Cycles, Steroids and Anabolic Steroids, buy steroids, steroid nation